Sign in

CIK 0001680581

  • Non-accelerated filer
  • Smaller reporting company

Fulcrum Therapeutics, Inc.

Sign in to watch
Ticker
FULC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
474839948
Phone
+1 617-651-8851
Business address
26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2021-04-01 Dunn Judith Grant or award · Stock Option (right to buy) +215,000 215,000
2021-03-31 Stuart Bryan Grant or award · Stock Option (right to buy) +350,000 350,000
2021-03-16 Gould Robert J Sale −789 $12.43 $10K 506,630
2021-03-15 Gould Robert J Sale −9,211 $12.13 $112K 507,419
2021-02-22 Thomson Peter G. VP Finance & Accounting Exercise or conversion +5,000 $7.84 $39K 20,212
2021-02-22 Thomson Peter G. VP Finance & Accounting Sale −5,000 $14.72 $74K 15,212
2021-02-22 Thomson Peter G. VP Finance & Accounting Exercise or conversion · Stock Option (right to buy) −5,000 50,471
2021-02-16 Gould Robert J Sale −6,542 $14.19 $93K 518,303
2021-02-16 Gould Robert J Sale −1,673 $14.56 $24K 516,630
2021-02-08 Moxham Christopher Chief Scientific Officer Grant or award · Stock Option (right to buy) +100,000 100,000
2021-02-02 Gould Robert J Grant or award · Stock Option (right to buy) +269,390 269,390
2021-01-25 Stuart Bryan Chief Operating Officer Grant or award · Stock Option (right to buy) +134,376 134,376
2021-01-25 Thomson Peter G. VP Finance & Accounting Grant or award · Stock Option (right to buy) +40,000 40,000
2021-01-21 Thomson Peter G. VP Finance & Accounting Sale −6,607 $14.00 $92K 15,212
2021-01-20 Gould Robert J Sale −10,000 $12.08 $121K 524,845
2020-12-03 Ezekowitz Alan Director Grant or award · Stock Option (right to buy) +15,000 15,000
2020-12-03 Oltmans Curtis Gale SVP, General Counsel Grant or award · Stock Option (right to buy) +153,600 153,600
2020-09-14 Wallace Owen B. Chief Scientific Officer Exercise or conversion +6,350 $7.84 $50K 133,438
2020-09-14 Wallace Owen B. Chief Scientific Officer Exercise or conversion · Stock Option (right to buy) −6,350 75,592
2020-07-08 Wallace Owen B. Chief Scientific Officer Exercise or conversion +2,951 $7.84 $23K 130,039

Page 9 of 15 · 291 trades